Javascript must be enabled to continue!
A Review Article on Analytical Method on Vericiguat
View through CrossRef
Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator used in the treatment of chronic heart failure, aimed at reducing hospitalization rates and improving cardiac function by inducing vasodilation. The analysis of Vericiguat in pharmaceutical formulations and biological fluids requires robust and precise analytical methods. High-Performance Liquid Chromatography (HPLC) and UV-Visible Spectrophotometry are the primary techniques employed for this purpose due to their high specificity, sensitivity, and rapid analysis capabilities. This review discusses the development, validation, and application of these analytical methods for Vericiguat. Various HPLC methods have been developed, utilizing different columns, mobile phases, and detection wavelengths to ensure the accurate quantification of Vericiguat in bulk and tablet dosage forms. UV-Visible spectrophotometry has also been employed, offering a simpler and cost-effective alternative for routine analysis. The review consolidates the key parameters and findings of these methods, highlighting their advantages and suitability for the effective analysis of Vericiguat, thereby contributing to quality assurance in pharmaceutical development and therapeutic monitoring
Title: A Review Article on Analytical Method on Vericiguat
Description:
Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator used in the treatment of chronic heart failure, aimed at reducing hospitalization rates and improving cardiac function by inducing vasodilation.
The analysis of Vericiguat in pharmaceutical formulations and biological fluids requires robust and precise analytical methods.
High-Performance Liquid Chromatography (HPLC) and UV-Visible Spectrophotometry are the primary techniques employed for this purpose due to their high specificity, sensitivity, and rapid analysis capabilities.
This review discusses the development, validation, and application of these analytical methods for Vericiguat.
Various HPLC methods have been developed, utilizing different columns, mobile phases, and detection wavelengths to ensure the accurate quantification of Vericiguat in bulk and tablet dosage forms.
UV-Visible spectrophotometry has also been employed, offering a simpler and cost-effective alternative for routine analysis.
The review consolidates the key parameters and findings of these methods, highlighting their advantages and suitability for the effective analysis of Vericiguat, thereby contributing to quality assurance in pharmaceutical development and therapeutic monitoring.
Related Results
Vericiguat and health status outcomes in heart failure with reduced ejection fraction: insights from the VICTORIA trial
Vericiguat and health status outcomes in heart failure with reduced ejection fraction: insights from the VICTORIA trial
Abstract
Background
In the VICTORIA trial, vericiguat compared with placebo reduced the risk of the primary endpoint of cardiova...
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Abstract
Background
In the VICTORIA trial (n=5050) the reduction in the primary composite endpoint of cardiovascular death (CVD)...
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
Background
Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection...
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Background
Although treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging condition, impacting over 10% of patients w...
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice
Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortalit...
EFFICACY OF VERICIGUAT IN A PATIENT WITH HFREF AND CLINICAL STABILITY, A CASE REPORT
EFFICACY OF VERICIGUAT IN A PATIENT WITH HFREF AND CLINICAL STABILITY, A CASE REPORT
Abstract
Heart failure (HF) is a syndrome whit complex etiology associated with high mortality and hospitalization risk, despite therapeutic progress. Recent ESC (Eu...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
A Short Review of New Drugs for Heart Failure: Omecamtiv Mecarbil and Vericiguat
A Short Review of New Drugs for Heart Failure: Omecamtiv Mecarbil and Vericiguat
Heart failure is associated with increased morbidity and mortality. Although developments of therapeutic agents have shown benefit and have improved the patients’ condition, there ...

